Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05908396
• Other study ID #: IGM-2644-001
• Status: Recruiting
• Phase: Phase 1
• Start date: August 2023
• Est. completion date: August 2026

Study information

• Verified date: August 2023
• Source: IGM Biosciences, Inc.
• Contact: IGM Clinical Trials
• Phone: (877) 544-6728
• Email: clinicaltrials[@]igmbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 60 months.

Description:

Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage. The escalation stage will investigate single agent IGM-2644 safety and tolerability in patients with relapsed and/or refractory multiple myeloma. The dose expansion cohort(s) will further evaluate safety, PK/PD, and preliminary efficacy of the recommended phase 2 dose (RP2D).

IGM-2644 will be administered intravenously (IV).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 2026
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults > 18 years at time of consent

• ECOG performance status of 0 or 1

• Relapsed and/or refractory multiple myeloma after = 3 prior lines; Must have failed treatment with an IMiD, PI, and anti-CD38 therapy

• Measurable disease per the IMWG response criteria

• Adequate marrow and organ function without transfusion or growth factor support within 7 days prior to screening

• Willing and able to undergo bone marrow aspirate and biopsy per protocol

Exclusion Criteria:

• Inability to comply with study and follow-up procedures

• History of clinically significant primary amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia or myelodysplastic syndrome

• Received chemotherapy, biologics, or small molecule therapy within 21 days or 5 half-lives, whichever is shorter

• Use of any non-approved or investigational agent = 4 weeks prior to the first dose of study drug.

• Received last prior anti-CD38 monoclonal antibody treatment within 28 days before first planned dose of the study drug

• Current Grade > 1 toxicity, with the exception of Grade 2 peripheral neuropathy, alopecia, or toxicities from prior anti-tumor therapy that are considered irreversible

• Large-field radiotherapy within 28 days prior to Day 1 (radiation to a single site as concurrent therapy is allowed)

• Prior autologous stem cell transplant within 180 days prior to Day 1

• Prior allogeneic stem cell transplant

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• IGM-2644
IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.

Locations

Country	Name	City	State
United States	Colorado Blood Cancer Institute	Denver	Colorado
United States	City of Hope	Duarte	California
United States	Tennessee Oncology (SCRI)	Nashville	Tennessee
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Fred Hutchinson Cancer Research Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
IGM Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and tolerability of IGM-2644 in participants with multiple myeloma, including estimation of the maximum tolerated dose (MTD) or maximum administered dose (MAD)	Incidence of treatment-emergent AEs, SAEs, and DLT per NCI CTCAE v5.0	From Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days)
Secondary	Area Under the Curve (AUC) of IGM-2644	Area Under the Curve (AUC) of IGM-2644 as a single agent	At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days)
Secondary	Clearance (CL) of IGM-2644	Clearance (CL) of IGM-2644	At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days)
Secondary	Maximum Plasma Concentration (Cmax) of IGM-2644	Maximum Plasma Concentration (Cmax) of IGM-2644 as a single agent	At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days)
Secondary	Half Life (HL) of IGM-2644	Half Life (HL) of IGM-2644 as a single agent	At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days)
Secondary	Anti-Drug Antibodies (ADA) Formation	To evaluate the immunogenicity of IGM-2644 as a single agent	At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days)
Secondary	Objective Response Rate (ORR)	To assess preliminary efficacy of IGM-2644 as a single agent, defined as the percentage of participants who achieve a confirmed complete response (CR), very good partial response (VGPR), or partial response (PR) per the International Myeloma Working Group (IMWG)	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 60 months
Secondary	Duration of Response (DoR)	For participants who demonstrate a confirmed complete response (CR), very good partial response (VGPR), or partial response (PR), defined as the time from the first documented response to the first documented disease progression or death, whichever occurs first.	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 60 months
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from first dose to the first documented disease progression per IMWG criteria by investigator or death, whichever occurs first.	At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 60 months